PODD|Analyst Targets
PODD|Company Info
PODD|Insider Trading
PODD|Fundamentals
PODD|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.59 | - | - |
| Q2'26 | $1.48 | $1.66 | +12.2% |
| Q1'26 | $1.19 | $1.42 | +19.3% |
| Q4'25 | $1.18 | $1.55 | +31.5% |
| Q3'25 | $1.15 | $1.24 | +8.1% |
| Q2'25 | $0.92 | $1.17 | +26.8% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $850M | - | - |
| Q2'26 | $803M | $802M | -0.2% |
| Q1'26 | $730M | $762M | +4.3% |
| Q4'25 | $714M | $784M | +9.7% |
| Q3'25 | - | $706M | - |
| Q2'25 | - | $649M | - |
PODD|Monthly Returns
Market Data
PODD Stock Snapshot
- Market cap
- 9.77B
- P/E ratio
- 26.0
- Day range
- $137.21 – $139.75
- News sentiment
- 45/100 · Neutral
- Analyst target
- $167.17 (+21.7%)
- Consensus
- Hold · 35 analysts
PODD is on the weaker side of its setup, with little confirmation for a reversal yet. Thinner liquidity means moves can extend past what the fundamentals alone justify.
Reverse DCF
What growth is priced into PODD?
At today's price, Insulet Corporation needs to grow free cash flow about 13.3% a year for the next 10 years to justify its valuation at a 8.55% cost of capital. Over its actual history it has compounded free cash flow at 132.1% a year, so the market is asking for 118.8 percentage points below its own delivered rate. On that basis PODD looks priced below what its own growth record supports.
- Implied FCF growth
- 13.3%
- Historical FCF CAGR
- 132.1%
- Growth gap
- -118.8 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 8.55%
- Beta
- 0.74
Behaviour On Record
What PODD's own history says about today's numbers
- Realized volatility (21d)
- 21.8% 8th pct
- Below its peak
- -60.8%
- vs 200-day average
- -26.8%
- Up days (1y)
- 47%
Insulet Corporation is currently running 21.8% annualised volatility over the last 21 sessions. Measured against PODD's own 13 years of daily returns rather than a market-wide average, that is the 8th percentile — unusually subdued by its own history, against a typical reading of 36.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
PODD is trading -60.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -32.7%, and the deepest was -61.3% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -26.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 7th percentile — a narrower gap than it typically runs. Over the past year PODD closed higher on 47% of sessions, and it is currently 1 session into a falling streak.
On October specifically: over 13 years of records, PODD finished the month higher 7 of 13 times, with a median return of +2.3% and an average of +0.4%. Its strongest month historically has been November at +10.6% on average, its weakest September at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: PODD has opened more than 2% away from the prior close in 165 of 3,267 sessions (5.1% of the time), with the largest gaps running +16.4% and -12.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, PODD moved an average of 4.9% in the session after earnings, closing higher 2 of those 3 times, with a median move of +5.3% and a largest of +6.0%.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against PODD's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of PODD's sector?
Insulet Corporation sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Medical Devices industry group, PODD ranks 3rd of 15 tracked industries, improving.
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 73
- Industry rank
- #3 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on PODD?
Jefferies most recently reiterated its rating on Insulet Corporation to Buy on Oct 12, 2026 with a price target of $190 (from $275). Over the last 90 days, coverage has run 0 upgrades against 5 downgrades, a net bearish lean.
- Latest action
- Jefferies — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 5
- Net rating momentum
- -5
Earnings Release, Scored
What did Insulet Corporation's latest earnings release say?
Most important lines
- 1
Adjusted operating income 1 of $154.5 million, or 19.3% of revenue, up over 140 basis points compared to prior year
- 2
Operating income of $129.7 million, or 16.2% of revenue, down 250 basis points over prior year
Negative tone - 3
Revenue of $801.7 million, up 23.5%, or 22.7% in constant currency, and exceeded the high end of the Company’s guidance range of 20% - 22% at constant currency rates
Peers & ETF holders
PODD peers & ETF holders
Medical DevicesMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▼ Sell | 8,701,472 | 12.35% | $2.47B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 6,690,192 | 9.50% | $1.02B | 2026-08-07 |
| AQR Capital Management LLC | ▲ Buy | 2,455,135 | 3.48% | $373.79M | 2026-08-14 |
| Baillie Gifford & Co | ▲ Buy | 2,042,313 | 2.90% | $310.94M | 2026-08-06 |
| Geode Capital Management, LLC | ▼ Sell | 2,003,861 | 2.84% | $303.97M | 2026-08-12 |
| Two Sigma Investments, LP | ▲ Buy | 1,903,734 | 2.70% | $289.84M | 2026-08-14 |
| Invesco Ltd. | ▲ Buy | 1,694,651 | 2.41% | $258.01M | 2026-08-14 |
| Morgan Stanley | ▲ Buy | 1,479,050 | 2.10% | $225.19M | 2026-08-13 |
| Norges Bank | ▼ Sell | 1,047,986 | 1.49% | $159.56M | 2026-08-12 |
| FMR LLC (Fidelity) | ▼ Sell | 964,297 | 1.37% | $146.81M | 2026-08-13 |
| Millennium Management LLC | ▲ Buy | 865,387 | 1.23% | $131.76M | 2026-08-14 |
| Goldman Sachs Group Inc | ▼ Sell | 818,265 | 1.16% | $124.58M | 2026-08-14 |
| Citadel Advisors LLC | ▲ Buy | 796,746 | 1.13% | $121.30M | 2026-09-02 |
| Northern Trust Corp | ▼ Sell | 649,908 | 0.92% | $98.95M | 2026-08-13 |
| JPMorgan Chase & Co | ▲ Buy | 595,123 | 0.84% | $94.39M | 2026-08-12 |
| Man Group plc | ▼ Sell | 517,217 | 0.73% | $78.75M | 2026-08-14 |
| D. E. Shaw & Co., Inc. | ▲ Buy | 426,520 | 0.61% | $64.94M | 2026-08-14 |
| Bank of America Corp | ▲ Buy | 426,409 | 0.61% | $64.92M | 2026-08-14 |
| Squarepoint Ops LLC | ▲ Buy | 267,642 | 0.38% | $40.75M | 2026-08-14 |
| Artisan Partners Limited Partnership | ▼ Sell | 260,245 | 0.37% | $39.62M | 2026-08-13 |
| Renaissance Technologies LLC | ▼ Sell | 202,083 | 0.29% | $30.77M | 2026-08-13 |
| Janus Henderson Group plc | ▲ Buy | 144,818 | 0.21% | $30.39M | 2026-05-18 |
| Capital World Investors | ▲ Buy | 172,712 | 0.25% | $26.30M | 2026-08-12 |
| Citigroup Inc | ▲ Buy | 158,903 | 0.23% | $24.19M | 2026-08-03 |
| Bridgewater Associates, LP | ▲ Buy | 156,413 | 0.22% | $23.81M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-09-18 | 2026-10-12 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-08-18 | 2026-09-10 |
| Tina Smith | Senate | MN | ▼ Sell | $100K - $250K | 2026-05-07 | 2026-05-10 |
| Tina Smith | Senate | MN | ▼ Sell | $100K - $250K | 2026-04-29 | 2026-05-10 |
| Tina Smith | Senate | MN | ▼ Sell | $50K - $100K | 2024-04-04 | 2024-04-19 |
| Tina Smith | Senate | MN | ▼ Sell | $250K - $500K | 2020-03-17 | 2020-04-16 |
| Tina Smith | Senate | MN | ▼ Sell | $15K - $50K | 2018-08-30 | 2018-09-19 |
| Tina Smith | Senate | MN | ▼ Sell | $100K - $250K | 2018-06-01 | 2018-06-11 |
| Tina Smith | Senate | MN | ▼ Sell | $100K - $250K | 2018-03-02 | 2018-03-06 |